TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
The latest announcement is out from Livzon Pharmaceutical Group ( (HK:1513) ).
Livzon Pharmaceutical Group Inc. has announced its unaudited interim results for the first half of 2025, in compliance with the listing rules of the Hong Kong Stock Exchange. The results, available in both Chinese and English, will be published on the company’s and HKEx’s websites, with printed copies dispatched to shareholders who have opted for them. This announcement reflects the company’s commitment to transparency and regulatory compliance, potentially strengthening its market position and stakeholder trust.
The most recent analyst rating on (HK:1513) stock is a Hold with a HK$30.00 price target. To see the full list of analyst forecasts on Livzon Pharmaceutical Group stock, see the HK:1513 Stock Forecast page.
More about Livzon Pharmaceutical Group
Livzon Pharmaceutical Group Inc. is a joint stock company incorporated in the People’s Republic of China, operating in the pharmaceutical industry. The company focuses on the production and distribution of pharmaceutical products and services, catering to both domestic and international markets.
Average Trading Volume: 2,287,696
Technical Sentiment Signal: Strong Buy
Current Market Cap: HK$37.91B
For detailed information about 1513 stock, go to TipRanks’ Stock Analysis page.